홈
마켓
차트 & 아이디어
Algo
뉴스
Store
브로커
다운로드
경제 달력
트레이딩 시그널
웹터미널
검색
/
타입: @user, $symbol
검색
로그인
계정을 생성하십시오
한국어
English
Русский
中文
Español
Português
日本語
Deutsch
Français
Italiano
Türkçe
CRDL
#5403
Cardiol Therapeutics Inc. Class A Common Shares
1.0
2
-0.97%
부문:
베이스:
수익 통화:
일일 변동 비율
년간 변동
일일 변동
-0.97%
월간 변동
+4.08%
6달 변화
-8.93%
년간 변동율
-13.56%
이전 종가
1.0
3
Open
1.0
2
Bid
Ask
Low
1.0
2
High
1.0
2
양
3
마켓
주식
헬스케어
CRDL
Open full chart
Financials
Overview
성명
Statistics
Dividends
Quarterly
Annual
Value
2022
2023
2024
TTM
Key stats
Total common shares outstanding
64.04 M
65.35 M
82.61 M
—
Valuation ratios
Enterprise value
34.59 M
57.51 M
105.74 M
—
Price to earnings ratio
—
—
—
—
Price to sales ratio
—
—
—
—
Price to cash flow ratio
—
—
—
—
Price to book ratio
—
—
—
—
Enterprise value to EBITDA ratio
—
—
—
—
Profitability ratios
Return on assets %
—
—
—
—
Return on equity %
—
—
—
—
Return on invested capital %
—
—
—
—
Gross margin %
—
—
—
—
Operating margin %
—
—
—
—
EBITDA margin %
—
—
—
—
Net margin %
—
—
—
—
Liquidity ratios
Quick ratio
—
—
—
—
Current ratio
—
—
—
—
Inventory turnover
—
—
—
—
Asset turnover
—
—
—
—
Solvency ratios
Debt to assets ratio
—
—
—
—
Debt to equity ratio
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
Per share metrics
Operating cash flow per share
—
—
—
—
EBIT per share
—
—
—
—
EBITDA per share
—
—
—
—
Total debt per share
—
—
—
—
Cash per share
—
—
—
—
Net current asset value per share
—
—
—
—
Tangible book value per share
—
—
—
—
Working capital per share
—
—
—
—
Book value per share
—
—
—
—
뉴스
카디올 테라퓨틱스, 2상 심근염 연구 결과 발표
Cardiol Therapeutics publishes phase II myocarditis study results
카디올 테라퓨틱스, 인수 계약 및 신주인수권 증서 계약서 제출
Cardiol Therapeutics files underwriting agreement and warrant indenture
카디올 테라퓨틱스, 1,350만 달러 규모 사모 발행 발표
Cardiol Therapeutics announces $13.5 million private placement
Cardiol Therapeutics, 167억 원 규모의 자금 조달 발표
Cardiol Therapeutics announces $13.5 million bought deal financing
Cardiol Therapeutics, 재발성 심낭염 임상시험 환자 등록 50% 달성
Cardiol Therapeutics reaches 50% enrollment in recurrent pericarditis trial
H.C. Wainwright, Cardiol Therapeutics에 ’매수’ 등급 재확인, 목표가 9달러
H.C. Wainwright reaffirms Buy rating on Cardiol Therapeutics stock at $9 target